ArticleFrontiers in cellular and infection microbiology2022
12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study.
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Admission Liver Injury Is an Independent Predictor of Early and Overall Mortality in Hospitalized Patients with Moderate-to-Critical COVID-19: A Retrospective Cohort Study.Life (Basel, Switzerland) · 2026Article
- Article
- Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years.Journal of clinical medicine · 2025Article
- Article
- Liver function abnormality on admission predicts long COVID syndrome in digestive system.Heliyon · 2024Article
- Clinico-radiological and pulmonary function assessment of post-COVID-19 patients with respiratory symptoms.Journal of family medicine and primary care · 2024Article
- Liver dysfunction in adults with COVID-19 infection: A longitudinal study with transient elastography evaluation.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Risks of digestive diseases in long COVID: evidence from a population-based cohort study.BMC medicine · 2024Article
- Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.Hepatology forum · 2024Review
- Influence of time factor and albuminuria on characteristics of patients with type 2 diabetes Mellitus before, during and 1 year after COVID-19 recovery.Diabetology & metabolic syndrome · 2023Article
- Enzymatic approaches against SARS-CoV-2 infection with an emphasis on the telomere-associated enzymes.Biotechnology letters · 2023Review
- Outcomes of COVID-19 among patients with liver disease.World journal of gastroenterology · 2023Review
- Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments.World journal of gastroenterology · 2023Review
- Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets.Frontiers in molecular biosciences · 2023Review
- Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study.Emerging microbes & infections · 2022Article
- Clinical predictors of recovery of COVID-19 associated-abnormal liver function test 2 months after hospital discharge.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The longitudinal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the liver are unknown. This study aimed to characterize dynamic changes in liver function test abnormalities in patients with COVID-19 at the acute phase and recovery phase. Methods: A prospective cohort study involved patients with COVID-19 who were admitted to Shenzhen Third People's Hospital between January 11, 2020, and April 27, 2020. Patients underwent liver function tests at hospitalization and at the outpatient visit at the 1-month, 3-month, 6-month, and 12-month follow-ups. Results: Among 461 patients, 28.4% of patients had any kind of liver function tests abnormality at admission, manifested as elevated ALT (13.0%), AST (17.6%), and GGT (15.8%) levels. The trajectory analysis indicated a marked improvement in liver function after discharge, with any kind of liver function test abnormalities of 25.1% at 1 month, 13.2% at 3 months, 16.7% at 6 months, and 13.2% at 12 months after discharge. Persistent liver function abnormalities were observed in patients with pre-existing conditions during follow-up. A significantly higher prevalence of ultrasound determined fatty liver disease was found in those patients with more frequent LFT abnormalities at follow-up. Conclusion: In this study of patients with COVID-19, liver damage in COVID-19 was usually temporary and could return to normal at the end of the 12-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.